229 related articles for article (PubMed ID: 34889301)
1. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
[TBL] [Abstract][Full Text] [Related]
2. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
Front Immunol; 2022; 13():984132. PubMed ID: 36189265
[TBL] [Abstract][Full Text] [Related]
3. A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.
Lopez AT; Geskin L
Oncologist; 2018 Oct; 23(10):1119-1126. PubMed ID: 30018132
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect.
Grimaux X; Delva R; Jadaud E; Croue A
Australas J Dermatol; 2019 Aug; 60(3):e235-e236. PubMed ID: 30592031
[No Abstract] [Full Text] [Related]
5. Concomitant nivolumab-associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma.
Khazaeli M; Grover R; Pei S
J Cutan Pathol; 2023 Jun; 50(6):520-523. PubMed ID: 36601731
[TBL] [Abstract][Full Text] [Related]
6. Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature.
Anastasopoulou A; Papaxoinis G; Diamantopoulos P; Christofidou E; Benopoulou O; Stratigos A; Gogas H
J Immunother; 2018 Apr; 41(3):164-167. PubMed ID: 29309291
[TBL] [Abstract][Full Text] [Related]
7. Bullous pemphigoid associated with the 480-mg nivolumab dose in a patient with metastatic renal cell carcinoma.
Palla AR; Smith E; Doll D
Immunotherapy; 2019 Oct; 11(14):1187-1192. PubMed ID: 31462105
[TBL] [Abstract][Full Text] [Related]
8. A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
Chalmers JR; Wojnarowska F; Kirtschig G; Mason J; Childs M; Whitham D; Harman K; Chapman A; Walton S; Schmidt E; Godec TR; Nunn AJ; Williams HC
Health Technol Assess; 2017 Mar; 21(10):1-90. PubMed ID: 28406394
[TBL] [Abstract][Full Text] [Related]
9. Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid.
Sowerby L; Dewan AK; Granter S; Gandhi L; LeBoeuf NR
JAMA Dermatol; 2017 Jun; 153(6):603-605. PubMed ID: 28355425
[No Abstract] [Full Text] [Related]
10. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
Aggarwal P
Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
[No Abstract] [Full Text] [Related]
11. Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review.
de Lorenzi C; André R; Vuilleumier A; Kaya G; Abosaleh M
Ann Dermatol Venereol; 2020 Mar; 147(3):221-227. PubMed ID: 31982173
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid.
Sadik CD; Langan EA; Grätz V; Zillikens D; Terheyden P
Front Immunol; 2019; 10():1934. PubMed ID: 31474998
[TBL] [Abstract][Full Text] [Related]
13. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
Cosimati A; Rossi L; Didona D; Forcella C; Didona B
J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
[TBL] [Abstract][Full Text] [Related]
14. A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab.
Bruni M; Moar A; Schena D; Girolomoni G
Dermatol Online J; 2022 Mar; 28(2):. PubMed ID: 35670683
[TBL] [Abstract][Full Text] [Related]
15. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab-induced localized genital bullous pemphigoid in a 60-year-old male.
Alvarado SM; Weston G; Murphy MJ; Stewart CL
J Cutan Pathol; 2022 May; 49(5):468-471. PubMed ID: 34881446
[TBL] [Abstract][Full Text] [Related]
17. A Case of Bullous Pemphigoid Associated With Nivolumab Therapy.
Gotera N; Weilg P; Heleno C; Ferrari-Gabilondo N
Cureus; 2022 May; 14(5):e24804. PubMed ID: 35686260
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab-induced lichen planus.
Yilmaz M; Mese SG; Celik U
J Oncol Pharm Pract; 2020 Apr; 26(3):758-760. PubMed ID: 31382865
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer.
Fujiwara R; Inamura K; Yuasa T; Numao N; Yamamoto S; Masuda H; Kawauchi A; Takeuchi K; Yonese J
Int J Clin Oncol; 2020 Jan; 25(1):151-157. PubMed ID: 31522314
[TBL] [Abstract][Full Text] [Related]
20. Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab.
Olsen E; Svoboda SA; Saikaly SK; Missall TA; Motaparthi K
Cureus; 2023 Aug; 15(8):e43230. PubMed ID: 37692698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
